跳至主要内容
临床试验/NCT02330081
NCT02330081已完成不适用

Mirasol System for Whole Blood: Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood in Healthy Volunteers

Terumo BCTbio2 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2015年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
22
试验地点
2
主要终点
Relative Platelet Survival

研究概览

简要总结

A total of twelve healthy volunteers will donate one unit of fresh whole blood. This unit will be treated with the Mirasol Pathogen Reduction Technology for Whole blood and then stored for 24h. At the end of storage, platelet concentrates will be separated from the unit, tested for key in vitro parameters and radiolabeled. On the same day (so 24h after the donation of whole blood), the volunteer will donate a fresh sample of whole blood. Platelets will be separated from this fresh sample and labeled with another radio-isotope. Then, the two radiolabeled platelet aliquots will be infused simultaneously and the recovery and survival of the two types of platelets will be measured.

详细描述

The study will be a prospective, single-center, single-arm, intra-subject controlled, open-label design.

Subjects will donate one unit of fresh whole blood. This unit will be treated with the Mirasol PRT System for whole blood and then stored for 24 hours ± 1 hour at 22 ± 2°C. At the end of storage, platelet concentrates will be separated from the unit according to the Biomedical Excellence for Safer Transfusion (BEST) procedures. An aliquot will be removed from the platelet concentrates for testing and for radiolabeling and reinfusion. The platelets in Mirasol-treated whole blood will be tested for key in vitro parameters directly after treatment (Day 0) and at the end of storage (Day 1). Sterility testing will also be conducted on the stored units.

An aliquot of the platelet concentrate separated from each unit of stored Mirasol-treated whole blood will be radiolabeled with either 111Indium Oxine or 51Chromium, and autologously infused. An intra-subject control will be utilized as per the BEST guidelines for platelet radiolabeling procedures. On the day of infusion, the subject will donate a fresh sample of whole blood. Platelets will be separated from this fresh sample and labeled with the radio-isotope that was not used to label the subject's Mirasol-treated platelet sample. The two radiolabeled platelet aliquots (Mirasol-treated and fresh control) will be infused simultaneously, and the recovery and survival of the two types of platelets will be measured according to standard institutional practice.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adult subjects, who meet the inclusion criteria defined by the Blood Center for whole blood donation.
  • Age ≥ 18 and < 70 years
  • Able to commit to the study follow-up schedule.
  • Subjects must have adequate antecubital venous access for whole blood collection and follow-up blood draws.
  • Subjects of child-bearing potential (female or male) must agree to use effective contraception per site guideline or abstain from heterosexual intercourse during the course of the study.
  • Female of childbearing potential must be willing to take a pregnancy test prior to infusion of radiolabeled platelets.
  • Subjects must agree to report adverse events (AEs) during the required reporting period.

排除标准

  • Use of medications that interfere with platelet function within 48 hours of planned whole blood collection.
  • Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation (e.g., pharmaceutical).
  • Inability to comply with the protocol in the opinion of the investigator.
  • Unable or unwilling to give informed consent.

研究组 & 干预措施

Mirasol

Experimental

Subject will be infused with two products at the same time:

  1. radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.
  2. radio-labeled platelets derived from subjects untreated fresh whole blood.

干预措施: Mirasol treatment of whole blood (Device)

结局指标

主要结局

Relative Platelet Survival

时间窗: Days 1 through 10 post-infusion

Mean survival time of platelets derived from Mirasol-treated whole blood (WB) units that had been stored for 24 ± 1 hours at 22 ± 2ºC as compared to the mean survival time of fresh platelets from the same donor, measured in hours. Platelets were isolated from both Mirasol-treated WB and from fresh WB from the same participant, radiolabeled with either 111Indium or 51Chromium, and these 2 radiolabeled platelet samples (ie, 1 untreated, fresh and 1 Mirasol-treated, stored) were combined and reinfused back to the same participant.

Platelet 24-hour Relative Recovery

时间窗: 24 hours

Relative recovery of platelets derived from Mirasol-treated whole blood (WB) units that had been stored for 24 ± 1 hours at 22 ± 2ºC, measured as a percentage of platelets derived from freshly collected WB from the same participant. Platelets were isolated from both Mirasol-treated WB and from fresh WB from the same participant, radiolabeled with either 111Indium or 51Chromium, and these 2 radiolabeled platelet samples (ie, 1 untreated, fresh and 1 Mirasol-treated, stored) were combined and reinfused back to the same participant.

次要结局

  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Hemoglobin(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - White Blood Cells(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - pH(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - pO2(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Potassium(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Hematocrit(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Lactate(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Platelets(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - CO2(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Plasma Free Hemoglobin(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Glucose(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)
  • in Vitro Characteristics of Whole Blood and Platelets Derived From Mirasol-treated Whole Blood - Hemolysis(Day 0 post-collection, day 0 post-illumination, day 1 post-storage)

研究者

发起方
Terumo BCTbio
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验